首頁 > 市場調查報告書 > 製藥

癌症生物標記

市場調查報告書

商品編碼

2035522

癌症生物標記市場規模、佔有率和成長分析：按生物標記類型、癌症類型、技術、應用、最終用戶和地區分類－2026-2033年產業預測

Cancer Biomarkers Market Size, Share, and Growth Analysis, By Biomarker Type (Genetic Biomarkers, Protein Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer), By Technology, By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月05日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球癌症生物標記市場價值為 266.1 億美元，預計到 2033 年將成長至 726.1 億美元，而 2025 年為 297.5 億美元，預測期（2026-2033 年）的複合年成長率為 11.8%。

全球癌症發生率的上升預計將推動對癌症生物標記需求的成長。對腫瘤學研究的大量投資以及人們對生物標記在癌症診斷和治療中益處的認知不斷提高，預計將為該領域的公司創造新的商機。基因療法和個人化醫療的興起預計將進一步擴大癌症生物標記的應用範圍。此外，生物標記研究的進展以及對非侵入性和微創手術日益成長的偏好，預計也將對市場產生積極影響。另一方面，臨床有效性和可重複性問題、醫療專業人員認知度低、倫理問題以及嚴格的監管要求等挑戰可能會阻礙未來的市場成長。

全球癌症生物標記市場成長要素

全球癌症生物標記市場的主要促進因素之一是癌症發病率的上升以及對早期診斷和個人化治療方案日益成長的需求。隨著人們對癌症對公共衛生影響的認知不斷提高，對有效篩檢方法和標靶治療的需求也日益迫切。生物技術和基因組學的進步顯著加速了生物標記的發現，並推動了創新診斷工具的開發，從而實現精準的患者分層和最佳化治療。此外，政府對癌症研究的支持和投入不斷增加，也進一步促進了市場成長，因為相關人員都在努力為癌症管理提供有效的解決方案。

全球癌症生物標記市場面臨的限制因素

全球癌症生物標記市場的主要限制因素之一是生物標記發現和檢驗相關的高昂研發成本。許多癌症生物標記需要大量的研究、臨床試驗和監管核准，這些過程既耗時又昂貴。這些流程帶來的經濟負擔往往限制了中小型生物技術公司進入市場和參與競爭的能力，可能減緩創新步伐，並限制患者獲得先進診斷檢測的機會。此外，生物標記檢測的保險報銷問題也進一步阻礙了市場成長，並導致醫療服務提供者和患者猶豫不決。

全球癌症生物標記市場趨勢

在全球癌症生物標記市場，一個顯著的趨勢是採用多體學方法進行生物標記開發。此策略整合了基因組學、轉錄組學、體學、代謝體學和表觀基因等多種體學學學科，建構全面的生物標記特徵譜，從而提高特異性和有效性。與以往僅關注單一分析物的傳統方法不同，多組學方法能夠提供癌症分子環境的整體觀點。這項創新加速了精準腫瘤學的發展，並提高了癌症生物標記的臨床效用和診斷準確性。因此，採用此策略的公司將在競爭激烈的市場中脫穎而出，成為產業領導者。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Siemens Healthineers AG
Bio-Rad Laboratories, Inc.
QIAGEN NV
Illumina, Inc.
Agilent Technologies, Inc.
PerkinElmer, Inc.
Becton, Dickinson and Company
Merck KGaA
Hologic, Inc.
Myriad Genetics, Inc.
Exact Sciences Corporation
Guardant Health, Inc.
Sysmex Corporation
Bio-Techne Corporation
Genomic Health, Inc.
Fujirebio Holdings, Inc.

結論與建議

簡介目錄

Product Code: SQMIG35H2355

Global Cancer Biomarkers Market size was valued at USD 26.61 billion in 2024 and is poised to grow from USD 29.75 billion in 2025 to USD 72.61 billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026-2033).

The increasing prevalence of cancer globally is anticipated to drive a heightened demand for cancer biomarkers. Significant investment in oncology research and growing awareness of the advantages of biomarkers in cancer diagnosis and treatment are expected to unlock new opportunities for companies in this sector. The rise in gene therapies and personalized medicine will likely further enhance the utilization of cancer biomarkers. Additionally, advancements in biomarker research and a growing preference for non-invasive and minimally invasive procedures are projected to benefit the market. Conversely, challenges such as issues related to clinical validity and reproducibility, limited awareness among healthcare professionals, ethical concerns, and stringent regulatory requirements may hinder future market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biomarkers Market Segments Analysis

Global Cancer Biomarkers Market is segmented by Biomarker Type, Cancer Type, Technology, Application, End User and region. Based on Biomarker Type, the market is segmented into Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-based Biomarkers, Imaging Biomarkers and Others. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Liver Cancer, Blood Cancer (Leukemia, Lymphoma, Myeloma) and Others. Based on Technology, the market is segmented into Omics Technologies, Immunoassays, PCR (Polymerase Chain Reaction), Next Generation Sequencing (NGS), Imaging Techniques and Others. Based on Application, the market is segmented into Diagnostics, Prognostics, Drug Discovery & Development, Personalized Medicine and Research Applications. Based on End User, the market is segmented into Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Contract Research Organizations (CROs) and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biomarkers Market

One key market driver for the global cancer biomarkers market is the increasing prevalence of cancer and the rising demand for early diagnostic and personalized treatment solutions. As awareness of cancer's impact on public health grows, the urgency for effective screening methods and targeted therapies becomes more pronounced. Advances in biotechnology and genomics have significantly enhanced biomarker discovery, facilitating the development of innovative diagnostic tools that enable precise patient stratification and treatment optimization. Additionally, supportive government initiatives and increased funding for cancer research further bolster the growth of this market, as stakeholders seek to provide effective solutions for cancer management.

Restraints in the Global Cancer Biomarkers Market

One key market restraint for the global cancer biomarkers market is the high cost of research and development associated with biomarker discovery and validation. Many cancer biomarkers require extensive studies, clinical trials, and regulatory approvals, which can be both time-consuming and expensive. The financial burden of these processes often limits the ability of smaller biotech firms to enter the market and compete, resulting in a slower pace of innovation and potentially restricted patient access to advanced diagnostic tests. Additionally, reimbursement challenges for biomarker-based tests further complicate market growth, leading to hesitance among healthcare providers and patients alike.

Market Trends of the Global Cancer Biomarkers Market

The Global Cancer Biomarkers market is witnessing a significant trend towards the adoption of a multi-omics approach in biomarker development. This strategy leverages the integration of various omics disciplines-genomics, transcriptomics, proteomics, metabolomics, and epigenomics-to create comprehensive biomarker signatures that enhance specificity and efficacy. By moving beyond traditional methods that focus on isolated analytes, the multi-omics approach provides a holistic view of the molecular landscape of cancer. This innovation accelerates the advancement of precision oncology, improving the clinical utility and diagnostic accuracy of cancer biomarkers, thereby positioning companies that embrace this strategy as leaders in a competitive market.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Cancer Biomarkers Market Size by Biomarker Type & CAGR (2026-2033)

Market Overview
Genetic Biomarkers
Protein Biomarkers
Metabolic Biomarkers
Cell-based Biomarkers
Imaging Biomarkers
Others

Global Cancer Biomarkers Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Liver Cancer
Blood Cancer (Leukemia, Lymphoma, Myeloma)
Others

Global Cancer Biomarkers Market Size by Technology & CAGR (2026-2033)

Market Overview
Omics Technologies
- Genomics
- Proteomics
- Metabolomics
Immunoassays
PCR (Polymerase Chain Reaction)
Next Generation Sequencing (NGS)
Imaging Techniques
Others

Global Cancer Biomarkers Market Size by Application & CAGR (2026-2033)

Market Overview
Diagnostics
Prognostics
Drug Discovery & Development
Personalized Medicine
Research Applications

Global Cancer Biomarkers Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Research & Academic Institutes
Contract Research Organizations (CROs)
Others

Global Cancer Biomarkers Market Size & CAGR (2026-2033)

North America (Biomarker Type, Cancer Type, Technology, Application, End User)
- US
- Canada
Europe (Biomarker Type, Cancer Type, Technology, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Biomarker Type, Cancer Type, Technology, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Biomarker Type, Cancer Type, Technology, Application, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Biomarker Type, Cancer Type, Technology, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Techne Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genomic Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujirebio Holdings, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments